Indoleamine-2,3-dioxygenase in an immunotherapy model for Ewing sarcoma

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Interleukin-2 (IL2) transgenic Ewing sarcoma cells demonstrate reduced tumor growth.
• Indoleamine-2,3-dioxygenase (IDO) is an immune-suppressive enzyme relevant to tumor progression.

Purpose of the Study:

• To analyze the expression of IDO in an IL2 transgenic Ewing sarcoma model.
• To investigate the impact of the cluster of differentiation 137 (CD137)/CD137 ligand (CD137L) co-stimulatory system on IDO expression and cytokine production.

Main Methods:

• IDO expression was assessed using polymerase chain reaction.
• In vivo and in vitro analyses were performed to evaluate the effects of the CD137/CD137L system.

Main Results:

• IDO was expressed in tumors developed in the presence of IL2 transgenic cells.
• CD137L transgenic tumor cells downregulated IDO expression.
• IDO expression in tumor cells was linked to interferon-gamma produced by lymphocytes in response to IL2.
• CD137 stimulation modulated lymphocyte cytokine production based on IL2 concentration.

Conclusions:

• The CD137/CD137L pathway plays a role in modulating the immune response against Ewing sarcoma.
• Targeting the CD137/CD137L pathway may offer therapeutic potential in Ewing sarcoma treatment.